1. 2331 Prognostic value of neutrophil/lymphocyte ratio in intestinal and pancreatic neuroendocrine tumors: exploratory analysis of data from the CLARINET trial of lanreotide depot/autogel. (September 2015) Authors: Grenader, T.; Ruszniewski, P.; Pavel, M.; Cwikła, J.; Phan, A.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.; Capdevila, J.; Wall, L.; Rindi, G.; Lang, A.; Gomez-Panzani, E.; Caplin, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2370 Relative risk analysis of safety profile of lanreotide autogel/depot vs. placebo in patients with pancreatic and intestinal neuroendocrine tumours. (September 2015) Authors: Phan, A.; Caplin, M.; Pavel, M.; Cwikła, J.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Wolin, E.; Capdevila, J.; Wall, L.; Rindi, G.; Langley, A.; Gomez-Panzani, E.; Ruszniewski, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S460 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2374 Multivariate analysis of progression-free survival in the CLARINET study of lanreotide Autogel/Depot vs placebo identifies prognostic factors in neuroendocrine tumours. (September 2015) Authors: Wolin, E.; Caplin, M.; Pavel, M.; Cwikła, J.; Phan, A.; Raderer, M.; Sedláčková, E.; Cadiot, G.; Capdevila, J.; Wall, L.; Rindi, G.; Langley, A.; Gomez-Panzani, E.; Ruszniewski, P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S461 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2389 Detection of SSTR2 and 5 expression in circulating tumour cells from patients with neuroendocrine tumours. (September 2015) Authors: Childs, A.; Vesely, C.; Ensell, L.; Caplin, M.; Toumpanakis, C.; Thirlwell, C.; Hartley, J.; Meyer, T. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S466 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 37LBA Telotristat etiprate is effective in treating patients with carcinoid syndrome that is inadequately controlled by somatostatin analog therapy (the phase 3 TELESTAR clinical trial). (September 2015) Authors: Kulke, M.H.; Horsch, D.; Caplin, M.; Anthony, L.; Bergsland, E.; Oberg, K.; Welin, S.; Warner, R.; Lombard-Bohas, C.; Kunz, P.; Grande, E.; Valle, J.; Fleming, D.; Lapuerta, P.; Banks, P.; Jackson, S.; Wheeler, D.; Zambrowicz, B.; Sands, A.; Pavel, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 6LBA 177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial. (September 2015) Authors: Strosberg, J.; Wolin, E.; Chasen, B.; Kulke, M.; Bushnell, D.; Caplin, M.; Baum, R.P.; Mittra, E.; Hobday, T.; Hendifar, A.; Oberg, K.; Lopera Sierra, M.; Ruszniewski, P.; Kwekkeboom, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S710 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Arcagen: Molecular profiling of rare cancer patients – analysis of the pilot study (87 patients). (October 2020) Authors: Morfouace, M.; Ray-Coquard, I.; Girard, N.; Stevovic, A.; Treilleux, I.; Meeus, P.; Aust, S.; Floquet, A.; Croce, S.; Seckl, M.; Gietema, J.; Caplin, M.; delaFouchardiere, C.; Licitra, L.; Kapiteijn, H.; Neumann, S. Piperno; Idbaih, A.; Blay, J.Y. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S32 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗